Given the exquisite sensitivity of RANKL-mediated disorders to denosumab, a lower dose, longer interval, or shorter treatment duration may be preferred to reduce the risk of hypercalcemia after discontinuation. This evidence concerns the gene TNFSF11 and hypercalcemia disease.